Other Events ·
On June 23, 2026, Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) conditionally…
QNRXQuoin Pharmaceuticals Ltd.
On June 23, 2026, Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) conditionally approved QYLEKI™ as the proposed brand name for QRX003. QRX003 is an investigational product candidate intended for the treatment of Netherton Syndrome. The company plans to include a request for final proprietary name approval for QYLEKI within its upcoming New Drug Application (NDA) for QRX003. Quoin Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases.